Summary

Global Biopsy Devices Market Size

The Biopsy Devices market is expected to grow from US$2.43 billion in 2024 to US$4.02 billion by 2033, with a CAGR of 5.75% from 2025 to 2033. Advancements in medical technologies, increasing prevalence of cancer and other chronic diseases, and the need for minimally invasive diagnostic procedures are driving this growth. The adoption of automated and precision biopsy devices in healthcare settings is also growing and supports the market.
Overview of Biopsy Devices Industry

Biopsy devices are medical instruments designed to take out a tissue sample from the body for examination and diagnosis. This is usually to check if there is a cancer, infection, or inflammatory disease. The biopsy devices are essential for the accurate diagnosis, the development of treatment plans, and the monitoring of the disease progression. The use of biopsy devices can vary based on the type of tissue and its location to be sampled for biopsies, such as needle biopsies, endoscopic biopsies, and surgical biopsies.

Core needle biopsy devices, FNA devices, and vacuum-assisted biopsy devices are common types of biopsy devices. These biopsy devices are minimally invasive, allowing healthcare professionals to extract tissue with minimal invasion, thus reducing patient discomfort and recovery time compared to the traditional surgical biopsies. Advancements in biopsy technology include image-guided biopsy devices that use ultrasound, CT scans, or MRI for greater precision, which have dramatically improved diagnostic accuracy. The Biopsy Devices Market is further driven by growth in oncology, where early detection of diseases is critical.


Growth Drivers for the Biopsy Devices Market

Increasing Incidence of Chronic Diseases

The increasing incidence of chronic diseases, particularly cancer, is a significant growth driver for the biopsy devices market. Early detection and accurate diagnosis are critical in managing conditions like cancer, where biopsy procedures are essential. As the global burden of cancer and other chronic diseases continues to rise, the demand for biopsy devices to perform diagnostic procedures is increasing, thereby driving market growth. Advancements in biopsy technology further support this demand for more precise and minimally invasive diagnostics.


Technological Advancements in Biopsy Devices

Technological advancement in biopsy devices propels the market forward as procedures become more precise, safe, and efficient. The latest developments, such as image-guided biopsy devices, using ultrasound, CT scans, or MRI, ensure more accurate targeting of tissue samples, thus reducing complications and improving diagnostic accuracy. Furthermore, minimally invasive biopsy tools, including vacuum-assisted and core needle biopsy devices, make the procedure faster, less painful, and with shorter recovery times, thus boosting adoption.


Rising Demand for Minimally Invasive Procedures

The increasing trend in the health care sector toward minimally invasive procedures has propelled the growth of the biopsy devices market. There are numerous advantages of minimally invasive biopsy techniques, including minimal discomfort for patients, quicker recovery, and shorter stay in the hospital. All these benefits have been considered of paramount importance in oncology because it demands regular biopsies to assess and decide the line of treatment. Thus, increasing awareness of these procedures further fuels the demand for biopsy devices and increases the size of the market.


Challenges in the Biopsy Devices Market

High Cost of Biopsy Procedures

The high cost of biopsy devices and procedures remains a significant challenge in the market. Advanced biopsy devices, particularly those with image-guided capabilities, can be expensive, which may limit their accessibility in low-resource settings. The overall cost of biopsy procedures, including hospital stays, imaging, and lab tests, can also be a barrier for patients, particularly in developing regions. This high cost limits widespread adoption and challenges healthcare providers aiming to implement cost-effective diagnostic solutions.


Risk of Complications and Inaccuracies

Although much improved through advanced technology, the risk of complications still exists in the form of bleeding, infection, and pain during a biopsy. Sometimes, inaccurate or unsuccessful biopsies can cause misdiagnosis or lead to repeated procedures, thereby delaying treatment. Furthermore, the complexity involved in performing biopsies from difficult locations or from tiny samples can pose a challenge. These risks can undermine the confidence of patients and slow down the adoption of new biopsy devices, especially in high-stakes procedures like cancer diagnosis.


Needle-Based Guns Biopsy Market

The Needle-Based Guns Biopsy Market refers to a segment of the larger biopsy devices market that utilize needle-based biopsy systems to sample tissues. Needle-based guns, also known as core needle biopsy guns, are widely utilized for obtaining tissue samples of various organs, such as breast, prostate, liver, and lungs. These devices use the spring-loaded mechanism to shoot a needle quickly into tissue, capturing a core sample with minimal invasiveness. The market for needle-based guns is growing due to the increasing demand for minimally invasive diagnostic procedures, as these devices reduce pain, have quicker recovery times, and lower risks of complications compared to traditional biopsy methods.


Lung Biopsy Market

The Lung Biopsy Market is an important part of the larger biopsy devices market, focusing on diagnostic procedures to obtain lung tissue samples. Lung biopsies are mainly used to diagnose lung cancer, infections, inflammation, or other respiratory conditions. The common procedures for lung biopsy include percutaneous needle biopsy, bronchoscopy-guided biopsy, and VATS biopsy. The increasing incidence of lung cancer, the main cause of cancer-related deaths globally, and the rising prevalence of other lung diseases are factors that drive the lung biopsy market. The latest techniques for biopsies, which include image-guided biopsies (ultrasound, CT scans, or MRI), enhance the accuracy and safety of lung biopsies, decrease the complications, and cut the recovery time for the patient. Moreover, other less invasive biopsy options that are using smaller incisions and fewer days of recovery increase market demand.


Biopsy Ultrasound-Guided Market

The Biopsy Ultrasound-Guided Market is developing with the increasing demand for less invasive diagnostic procedures having a high degree of accuracy. Ultrasound-guided biopsies make use of real-time imaging to guide the needle to the exact location of abnormal tissue, ensuring that samples are taken accurately. It is most commonly used in liver, breast, prostate, and kidney biopsies, reducing the risk of complications and increasing the success rate of the procedure. Increasing cancer cases, health awareness, and developments in ultrasound technologies are major drivers for the growth of this market.


Diagnostic & Imaging Center Biopsy Market

The Diagnostic & Imaging Center Biopsy Market is growing because diagnostic and imaging centers are increasingly playing a central role in the performance of biopsy procedures. Advanced imaging technologies, including CT scans, MRI, and ultrasound, are used to guide biopsies with greater precision and lower risks. Advances in both cancers and chronic disease frequencies; and the demand in general for minimally-invasive accurate diagnostic procedures are catalysts for growth in the industry. Furthermore, the expanded uptake of specialized imaging during the biopsy procedure improves biopsy-center efficiency and success levels while yielding diagnoses.


Canada Biopsy Devices Market

The Canada Biopsy Devices Market is increasing because of the growing demand for accurate and minimally invasive diagnostic tools, especially in oncology and chronic disease diagnosis. A major driver for the adoption of biopsy devices in Canada is the prevalence of cancer, particularly breast, prostate, and lung cancer. In addition, the focus on early diagnosis and precision medicine by the healthcare sector fosters market growth. Advances in technologies include image-guided biopsies and the invention of newer, more effective and easier devices for patients; it expands the biopsy devices market of Canada further. Aug 2022, The Mammotome DualCore TM biopsy system is available for ordering now by clinicians in the United States and Canada.


Biopsy Devices Market of France

The France Biopsy Devices Market is growing steadily with the rising need for precise and minimally invasive diagnostic techniques, especially in cancer detection. Rising incidences of cancers, such as breast, prostate, and lung cancer, are driving the demand for biopsy devices in France. Moreover, advanced technologies like image-guided biopsies, which increase accuracy and reduce complications, are gaining popularity and further fueling market growth. France's health care system, which focuses on early diagnosis and patient care, also contributes to the market's growth. September 2023, Roche France, Foundation Medicine, and the Institute Gustave Roussy have collaborated to provide in-house liquid biopsy genomic testing for cancer patients in France.


China Biopsy Devices Market

The China Biopsy Devices Market is growing rapidly, driven by the increasing prevalence of cancer and other chronic diseases that require accurate diagnostic procedures. With a growing aging population and increasing awareness about early disease detection, there is a higher demand for biopsy devices in China. Additionally, advancements in biopsy technology, such as image-guided and minimally invasive devices, are improving accuracy and reducing patient recovery time. The country's healthcare system is evolving, with more hospitals and diagnostic centers adopting cutting-edge biopsy technologies, further fueling market growth. March 2024: Chinese regulatory authorities have cleared Intuitive Surgical to market its Ion surgical robot system.


UAE Biopsy Devices Market

The UAE Biopsy Devices Market is growing, mainly driven by increasing healthcare investments and the rising prevalence of chronic diseases, especially cancer. There is a growing demand for modern diagnostic tools, such as biopsy devices, in order to detect diseases accurately and earlier in the UAE. The adoption of minimally invasive procedures such as image-guided biopsies is on the increase due to their benefits that reduce recovery times and a relatively lower complication rate. November 2024, The Abu Dhabi Public Health Centre in cooperation with M42 introduces an entirely non-invasive test, known as liquid biopsy for blood-based colorectal cancer screening.


Product – Market breakup in 5 viewpoints:
1. Needle-Based Guns
2. Biopsy Guidance Systems
3. Biopsy Needles
4. Biopsy Forceps
5. Others


Application – Market breakup in 6 viewpoints:
1. Breast Biopsy
2. Lung Biopsy
3. Prostate Biopsy
4. Liver Biopsy
5. Gastroenterology Biopsy
6. Others


Technology – Market breakup in 5 viewpoints:
1. CT Scan
2. Stereotactic Guided
3. Ultrasound Guided
4. MRI Guided
5. Others


End-User – Market breakup in 3 viewpoints:
1. Hospitals
2. Diagnostic & Imaging Center
3. Others


Country – Market of 25 Countries Covered in the Report:
1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherland
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa


All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Development
• Revenue Analysis


Company Analysis:
1. Cardinal Health, Inc.
2. Hologic, Inc.
3. Danaher Corporation
4. Becton, Dickinson and Company
5. Boston Scientific Corporation
6. Medtronic plc.
7. Olympus Corporation
8. CONMED Corporation

ページTOPに戻る

Table of Contents

1. Introduction


2. Research Methodology


3. Executive Summary


4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges


5. Global Biopsy Devices Market


6. Market Share
6.1 By Product
6.2 By Application
6.3 By Technology
6.4 By End User
6.5 By Countries


7. Product
7.1 Needle-Based Guns
7.2 Biopsy Guidance Systems
7.3 Biopsy Needles
7.4 Biopsy Forceps
7.5 Others


8. Application
8.1 Breast Biopsy
8.2 Lung Biopsy
8.3 Prostate Biospy
8.4 Liver Biopsy
8.5 Gastroenterology Biopsy
8.6 Others


9. Technology
9.1 CT Scan
9.2 Stereotactic Guided
9.3 Ultrasound Guided
9.4 MRI Guided
9.5 Others


10. End User
10.1 Hospitals
10.2 Diagnostic & Imaging Center
10.3 Others


11. Countries
11.1 North America

11.1.1 United States
11.1.2 Canada

11.2 Europe

11.2.1 France
11.2.2 Germany
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Belgium
11.2.7 Netherland
11.2.8 Turkey

11.3 Asia Pacific

11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Thailand
11.3.6 Malaysia
11.3.7 Indonesia
11.3.8 Australia
11.3.9 New Zealand

11.4 Latin America

11.4.1 Brazil
11.4.2 Mexico
11.4.3 Argentina

11.5 Middle East & Africa

11.5.1 Saudi Arabia
11.5.2 UAE
11.5.3 South Africa


12. Porter’s Five Forces Analysis
12.1 Bargaining Power of Buyers
12.2 Bargaining Power of Suppliers
12.3 Degree of Rivalry
12.4 Threat of New Entrants
12.5 Threat of Substitutes


13. SWOT Analysis
13.1 Strength
13.2 Weakness
13.3 Opportunity
13.4 Threat


14. Key Players Analysis
14.1 Cardinal Health, Inc.

14.1.1 Overview
14.1.2 Recent Development
14.1.3 Revenue Analysis

14.2 Hologic, Inc.

14.2.1 Overview
14.2.2 Recent Development
14.2.3 Revenue Analysis

14.3 Danaher Corporation

14.3.1 Overview
14.3.2 Recent Development
14.3.3 Revenue Analysis

14.4 Becton, Dickinson and Company

14.4.1 Overview
14.4.2 Recent Development
14.4.3 Revenue Analysis

14.5 Boston Scientific Corporation

14.5.1 Overview
14.5.2 Recent Development
14.5.3 Revenue Analysis

14.6 Medtronic plc.

14.6.1 Overview
14.6.2 Recent Development
14.6.3 Revenue Analysis

14.7 Olympus Corporation

14.7.1 Overview
14.7.2 Recent Development
14.7.3 Revenue Analysis

14.8 CONMED Corporation

14.8.1 Overview
14.8.2 Recent Development
14.8.3 Revenue Analysis